Field & Main Bank Takes Position in Amgen Amid Strong Financial Performance

Field & Main Bank has acquired a new stake in Amgen Inc. (NASDAQ:AMGN), a global biotechnology company, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund purchased 7,076 shares of the medical research company's stock, valued at approximately $2,562,000.

This is not an isolated instance; other hedge funds and institutional investors have also increased their positions in Amgen. Brighton Jones LLC, for example, grew its position by 23.5% during the fourth quarter, while Sivia Capital Partners LLC raised its stake by 10.6% in the second quarter.

Amgen's recent financial performance has been strong, with the company exceeding analyst expectations for both earnings and revenue in its latest reported quarter. Revenue increased year over year, and full-year guidance remains supportive of the stock's price near its 52-week high.

The company also announced a quarterly dividend, which will be paid on Friday, September 11th, to stockholders of record as of August 21st.